Table 3.

Clinical trials of mRNA encoding an immunostimulant.

Immune-stimulant	Brand	Title	Conditions	NCT Number	Phase	Study Start	Status
IL-12sc, IL-15 sushi, GM-CSF, IFNα	SAR441000 (BNT131)	A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Metastatic Neoplasm	NCT03871348	Phase 1	January 3, 2019	Recruiting
Optimized IL-2	BNT151	BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors	Multiple solid tumors	NCT04455620	Phase 1/2	January 26, 2021	Recruiting
IL-7,IL-2	BNT152, BNT153	Dose Escalation Trial of BNT152+153 in Patients With Cancer	Solid Tumor	NCT04710043	Phase 1	June 8, 2021	Recruiting
TLR7/8, RIG-1	CV8102	Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC	Skin cancer	NCT03291002	Phase 1	September 25, 2017	Active, not recruiting
OX40L	mRNA-2416	Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies	Relapsed/Refractory Solid Tumor Malignancies or Lymphoma Ovarian Cancer	NCT03323398	Phase 1/2	August 9, 2017	Active, not recruiting
OX40L, IL-23, IL-36γ	mRNA-2752	Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies	Relapsed/Refractory Solid Tumor Malignancies or Lymphoma	NCT03739931	Phase 1	November 27, 2018	Recruiting
IL-12	MEDI1191	A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors	Solid Tumors Cancer	NCT03946800	Phase 1	May 8, 2019	Recruiting